SCHEMBL12852246

SCHEMBL12852246

CC(=O)[C@H](N)CS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866882 1.00
SCHEMBL5943374 1.00
Cysteine SCHEMBL21747580 0.78 PTGS1 (0.84)
SCHEMBL17071957 0.78
SCHEMBL16704942 0.78
Cysteine SCHEMBL27613026 0.78 PTGS1 (0.84)
SCHEMBL11891014 0.78
SCHEMBL8583187 0.77
Cysteine SCHEMBL6244297 0.76 PTGS1 (0.80)
Cysteine SCHEMBL1275659 0.76 PTGS1 (0.80)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306550-A1 HYDROGELS FOR CELL THERAPY Adocia (FR) 2024-01-17 EP disclosed
WO-2023086557-A1 NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
US-20220016153-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-20 US disclosed
US-20210308168-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-07 US disclosed
WO-2021159044-A1 N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO EMORY UNIVERSITY (US) 2021-08-12 WO disclosed
WO-2021137913-A2 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2021-07-08 WO disclosed
US-10759748-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2020-09-01 US disclosed
US-20200123261-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES LLC 2020-04-23 US disclosed
WO-2019173602-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2019-09-12 WO disclosed
US-20150099806-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2015-04-09 US disclosed
US-8916609-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2014-12-23 US disclosed
US-20120316236-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2012-12-13 US disclosed
US-8288351-B2 Antagonists of the bradykinin B1 receptor AMGEN INC. (US) 2012-10-16 US disclosed
US-8278280-B2 Antagonists of the bradykinin B1 receptor AMGEN INC. (US) 2012-10-02 US disclosed
US-20090048149-A1 Antagonists of the bradykinin B1 receptor AMGEN INC. 2009-02-19 US disclosed